IQVIA (NYSE:IQV) Reaches New 52-Week Low Following Analyst Downgrade

IQVIA Holdings Inc. (NYSE:IQV)’s share price reached a new 52-week low on Wednesday after Citigroup lowered their price target on the stock from $225.00 to $210.00. Citigroup currently has a neutral rating on the stock. IQVIA traded as low as $179.28 and last traded at $183.75, with a volume of 1649439 shares traded. The stock had previously closed at $184.85.

IQV has been the subject of a number of other research reports. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Robert W. Baird cut their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

Institutional Trading of IQVIA

Hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter valued at about $27,000. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter valued at about $33,000. Avior Wealth Management LLC increased its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter valued at about $39,000. Finally, Lee Danner & Bass Inc. bought a new position in IQVIA in the 4th quarter valued at about $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Trading Down 0.2 %

The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market capitalization of $32.70 billion, a P/E ratio of 24.73, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The firm’s fifty day simple moving average is $197.95 and its 200 day simple moving average is $213.47.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.